Concepedia

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine

Masoud Etemadifar, Nahad Sedaghat, Hosein Nouri, Noushin Lotfi, Ahmad Chitsaz, Reza Khorvash, Hamed Zolfaghari, Alireza Ghasemi Movaghar, Mohammad Pourabbas, Mehri Salari

Multiple Sclerosis and Related Disorders · 2021 · 23 citations · 19 references

DOIFull text

Open access

Concepts

References

19

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

New England Journal of Medicine · 2021 · 1.8K citations · Full text

, , +17

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

New England Journal of Medicine · 2021 · 862 citations · Full text

, , +17

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis, Mihir Kakara, Mark M. Painter et al. · Nature Medicine · 2021 · 543 citations · Full text

, , +17

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster et al. · Therapeutic Advances in Neurological Disorders · 2021 · 362 citations · Full text

, , +17

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Maria Pia Sormani, Matilde Inglese, Irene Schiavetti et al. · EBioMedicine · 2021 · 224 citations · Full text

, , +17